The Effect of Anaerobically Cultivated Human Intestinal Microbiota Compared to Fecal Microbiota Transplantation on Gut Microbiota Profile and Symptoms of Irritable Bowel Syndrome, a Double-Blind Placebo-Controlled Study

Overview

Journal Microorganisms

Specialty Microbiology

Date 2022 Sep 23

PMID 36144420

Authors

Tarek Mazzawi

Trygve Hausken

Per Forde Refsnes

Jan Gunnar Hatlebakk

Gulen Arslan Lied

Affiliations

Soon will be listed here.

Abstract

Fecal microbiota transplantation (FMT) from healthy donors has been shown to improve the symptoms of irritable bowel syndrome (IBS) and changes the profile of the gut microbiota for the recipients. Alternatively, anaerobically cultivated human intestinal microbiota (ACHIM) can be used to manipulate the gut microbiota. The aim of the current study was to compare the efficacy and safety of ACHIM suspension with donor-FMT and placebo (patient's own feces) to treat IBS. Out of the 62 originally included eligible patients with diarrhea-predominant IBS and their respective donors, only 43 patients completed the study by answering the questionnaires and delivering fecal samples before transplantation and after 1, 4, 12 and 24 weeks. The patients were randomized into three subgroups for receiving ACHIM suspension ( = 17), donor-FMT ( = 11), or placebo ( = 15), and were followed up for 24 weeks. Fecal samples were analyzed by sequencing 16S rRNA gene using the GA-map Dysbiosis Test (Genetic Analysis AS, Oslo, Norway). IBS symptom questionnaires improved in all three subgroups. Bacterial strain signals in IBS patients were more significant for spp. and spp. after receiving donor-FMT compared to placebo and for before and after treatment in the subgroups of ACHIM and donor-FMT vs. placebo. These signals change after treatment with ACHIM suspension and donor FMT towards those measured for healthy controls, but not after placebo. IBS symptom questionnaires improved in all three forms of transplantation. Some bacterial strain signals were significantly different between ACHIM and donor-FMT vs. placebo. However, the placebo subgroup failed to change the gut microbiota towards signals measured for healthy controls. The safety and efficacy of ACHIM and donor-FMT seems similar in the current study, but further larger studies are needed.

Citing Articles

Clinical efficacy and safety of faecal microbiota transplantation in the treatment of irritable bowel syndrome: a systematic review, meta-analysis and trial sequential analysis.

Lo S, Hung T, Lin Y, Lee C, Chen C, Fang C Eur J Med Res. 2024; 29(1):464.

PMID: 39289768 PMC: 11409544. DOI: 10.1186/s40001-024-02046-5.

Fecal microbiota transplantation influences microbiota without connection to symptom relief in irritable bowel syndrome patients.

Hartikainen A, Jalanka J, Lahtinen P, Ponsero A, Mertsalmi T, Finnegan L NPJ Biofilms Microbiomes. 2024; 10(1):73.

PMID: 39191760 PMC: 11349920. DOI: 10.1038/s41522-024-00549-x.

Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Wang M, Xie X, Zhao S, Ma X, Wang Z, Zhang Y Front Immunol. 2023; 14:1136343.

PMID: 37275867 PMC: 10234428. DOI: 10.3389/fimmu.2023.1136343.

References

Whorwell P, Altringer L, Morel J, Bond Y, Charbonneau D, OMahony L . Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101(7):1581-90. DOI: 10.1111/j.1572-0241.2006.00734.x. View

Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S . Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2009; 22(5):512-9, e114-5. DOI: 10.1111/j.1365-2982.2009.01427.x. View

Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J . The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133(1):24-33. DOI: 10.1053/j.gastro.2007.04.005. View

Sugaya N, Nomura S, Shimada H . Relationship between cognitive factors and anxiety in individuals with irritable bowel syndrome. Int J Behav Med. 2011; 19(3):308-15. DOI: 10.1007/s12529-011-9195-0. View

Ley R, Turnbaugh P, Klein S, Gordon J . Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022-3. DOI: 10.1038/4441022a. View

Hoffmann-Vold A, Fretheim H, Sarna V, Barua I, Carstens M, Distler O . Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. BMJ Open. 2021; 11(6):e048541. PMC: 8231046. DOI: 10.1136/bmjopen-2020-048541. View

Thijssen A, Jonkers D, Leue C, van der Veek P, Vidakovic-Vukic M, van Rood Y . Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. J Clin Gastroenterol. 2010; 44(10):e236-41. DOI: 10.1097/MCG.0b013e3181eed5d8. View

Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad Jr H . Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013; 56(6):597-601. DOI: 10.1097/MPG.0b013e318292fa0d. View

Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R . European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017; 66(4):569-580. PMC: 5529972. DOI: 10.1136/gutjnl-2016-313017. View

10.

Mazzawi T, Lied G, Sangnes D, El-Salhy M, Hov J, Gilja O . The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. PLoS One. 2018; 13(11):e0194904. PMC: 6235238. DOI: 10.1371/journal.pone.0194904. View

11.

Li J, Sung C, Lee N, Ni Y, Pihlajamaki J, Panagiotou G . Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016; 113(9):E1306-15. PMC: 4780612. DOI: 10.1073/pnas.1518189113. View

12.

Oka P, Parr H, Barberio B, Black C, Savarino E, Ford A . Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(10):908-917. DOI: 10.1016/S2468-1253(20)30217-X. View

13.

Casen C, Vebo H, Sekelja M, Hegge F, Karlsson M, Ciemniejewska E . Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015; 42(1):71-83. PMC: 5029765. DOI: 10.1111/apt.13236. View

14.

El-Salhy M, Hatlebakk J, Gilja O, Hausken T . Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol Hepatol. 2014; 8(4):435-43. DOI: 10.1586/17474124.2014.888952. View

15.

Sandler R, Everhart J, Donowitz M, Adams E, Cronin K, Goodman C . The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122(5):1500-11. DOI: 10.1053/gast.2002.32978. View

16.

Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D . Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2016; 66(5):980-982. PMC: 5531219. DOI: 10.1136/gutjnl-2016-312513. View

17.

El-Salhy M, Hatlebakk J, Gilja O, Kristoffersen A, Hausken T . Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2019; 69(5):859-867. PMC: 7229896. DOI: 10.1136/gutjnl-2019-319630. View

18.

Johnsen P, Hilpusch F, Cavanagh J, Sande Leikanger I, Kolstad C, Valle P . Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2017; 3(1):17-24. DOI: 10.1016/S2468-1253(17)30338-2. View

19.

Codling C, OMahony L, Shanahan F, Quigley E, Marchesi J . A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2009; 55(2):392-7. DOI: 10.1007/s10620-009-0934-x. View

20.

Crow J, Davis S, Chaykosky D, Smith T, Smith J . Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection. Pharmacotherapy. 2015; 35(11):1016-25. DOI: 10.1002/phar.1644. View